Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market

Kostas Biliouris, an analyst from BMO Capital, maintained the Buy rating on Jasper Therapeutics (JSPR – Research Report). The associated price target is $15.00.

Kostas Biliouris has given his Buy rating due to a combination of factors related to the potential of Jasper Therapeutics’ drug, Briquilimab, in the chronic spontaneous urticaria (CSU) market. The upcoming data release in July/August is expected to include results from higher doses, which could differentiate Briquilimab from competitors like Barzolvolimab. This differentiation is crucial as it could capture a significant share of the large CSU market, which consists of 15-30 million patients in the US.
Biliouris notes that the current valuation of Jasper Therapeutics already discounts Briquilimab, suggesting that positive data could lead to a substantial increase in the stock price, potentially by 50-100% or more. The analyst highlights that Briquilimab has shown promising efficacy and safety profiles compared to its competitor, and the anticipated data could further establish a strong dose-response relationship. This potential upside and competitive advantage underpin Biliouris’s optimistic outlook and Buy rating for the stock.

In another report released on May 15, Oppenheimer also maintained a Buy rating on the stock with a $65.00 price target.